K-757 and K-833 combination for Obesity

"Individuals aged between 18 and 70 with a diagnosis of type 2 diabetes are eligible for enrollment in this research study, which aims to recruit approximately 32 participants."

"Given the preliminary nature of this trial as a Phase 1 study, the safety evaluation for the K-757 and K-833 combination has been rated at level 1 by our team."

"The main objective of this research, to be assessed within a period extending Up to Day 43 +/- 2 days, is the percentage of participants who halt the study medication due to an adverse event. Secondary goals encompass determining plasma K-757 Clearance [Cl] when used alongside K-833, Time at which plasma K-757 reaches maximum concentration [Tmax] in conjunction with K-833, and Tmax for plasma K-833 in combination with K-757."

"Indeed, the data on clinicaltrials.gov indicates that this particular clinical trial is actively seeking candidates. Initially shared on 12/7/2023 and last revised on 3/5/2024, the study aims to recruit a total of 32 participants from one designated location."

"Indeed, data available on clinicaltrials.gov indicates that this clinical investigation is currently seeking eligible individuals. Initially published on December 7th, 2023, the trial was last revised on March 5th, 2024. The objective is to recruit a total of 32 patients from one designated site."

"Eligible candidates for this research study must fall within the age bracket of 18 to 70 years. Notably, there are a total of 375 investigations catering to individuals below 18 years old and 1764 studies dedicated to those above 65 years of age."